Page last updated: 2024-10-27

gemfibrozil and Atherosclerosis

gemfibrozil has been researched along with Atherosclerosis in 10 studies

Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.

Research Excerpts

ExcerptRelevanceReference
"Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease."2.43Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's9 (90.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fruchart, JC2
Santos, RD1
Rembold, CM1
Lewis, SJ1
Rosenson, RS1
Calkin, AC2
Cooper, ME1
Jandeleit-Dahm, KA2
Allen, TJ2
Duriez, P1
Lassila, M1
Tikellis, C1
Thomas, MC1
Guzik, TJ1
Harrison, DG1
Bouhlel, MA1
Staels, B1
Chinetti-Gbaguidi, G1
Brinton, EA1

Reviews

5 reviews available for gemfibrozil and Atherosclerosis

ArticleYear
SPPARM alpha: the Lazarus effect.
    Current opinion in lipidology, 2019, Volume: 30, Issue:6

    Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib

2019
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
    Current opinion in cardiology, 2005, Volume: 20, Issue:4

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypoli

2005
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Drugs of today (Barcelona, Spain : 1998), 2006, Volume: 42, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol,

2006
Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
    Journal of internal medicine, 2008, Volume: 263, Issue:1

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Fenofibrate; Gemfib

2008
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
    Current atherosclerosis reports, 2008, Volume: 10, Issue:1

    Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D

2008

Other Studies

5 other studies available for gemfibrozil and Atherosclerosis

ArticleYear
To statin or to non-statin in coronary disease-considering absolute risk is the answer.
    Atherosclerosis, 2008, Volume: 200, Issue:2

    Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Aci

2008
Prevention and treatment of atherosclerosis: a practitioner's guide for 2008.
    The American journal of medicine, 2009, Volume: 122, Issue:1 Suppl

    Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Eicosapentaenoic Acid

2009
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.
    Diabetologia, 2006, Volume: 49, Issue:4

    Topics: Angiotensins; Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Diabetes Mellitus, Experiment

2006
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
    Atherosclerosis, 2007, Volume: 195, Issue:1

    Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Cell Adhesion;

2007
Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
    Circulation research, 2007, Aug-03, Volume: 101, Issue:3

    Topics: Albuminuria; Angiotensin II; Animals; Atherosclerosis; Endothelium, Vascular; Fibrosis; Gemfibrozil;

2007